The Kenya Medical Research Institute is conducting groundbreaking research to develop a vaccine protecting newborns from infectious diseases contracted in hospitals shortly after birth. The initiative addresses rising concerns over hospital-acquired infections among infants, especially preterm or low-birth-weight ones who remain under medical observation for extended periods. If successful, KEMRI’s maternal vaccine could position Kenya as a leader in neonatal health innovation across Africa.
The Kenya Medical Research Institute (KEMRI) is conducting groundbreaking research to develop a vaccine that could protect newborns from infectious diseases contracted in hospitals shortly after birth. The initiative comes amid rising concerns over hospital-acquired infections among infants, especially those born preterm or with low birth weight, who often remain in hospitals for extended periods under medical observation before discharge.
Findings from a KEMRI study conducted between 2020 and 2023 across several hospitals revealed a worrying increase in neonatal infections, highlighting the urgent need for stronger infection control measures in healthcare facilities. The study attributed the spike in infections to overcrowded wards, poor sanitation, and limited access to clean water, warning that without improved hygiene standards, many newborns will remain at risk of life-threatening infections.
KEMRI researchers identified Klebsiella pneumoniae, a highly medication-resistant bacterium, as one of the main causes of hospital-acquired infections in newborns. The identified bacteria often thrive in hospital environments and are resistant to most antibiotics, making treatment extremely difficult.
“So what we’ve noticed with neonates is that when they’re admitted, especially preterm or low-birth-weight babies, they are highly susceptible to bacteria,” said one KEMRI researcher, adding that “unfortunately, the bacteria they encounter in hospitals are often highly resistant.”
According to KEMRI, the new research aims to develop a maternal vaccine that would protect babies indirectly through their mothers. In this case, mothers would receive the vaccine during pregnancy, allowing them to pass on protective antibodies to their newborns.
“The idea is to give mothers immunity against Klebsiella so that when they give birth, their children are protected from infection,” the researcher explained.
Health experts have described this approach as a potentially lifesaving breakthrough, particularly for developing countries such as Kenya, where neonatal infections remain a major cause of infant mortality.
If successful, KEMRI’s maternal vaccine could position Kenya as a leader in neonatal health innovation, offering new hope for thousands of vulnerable newborns across Africa.
